Clinical trial NCT00763139: Inflammation and Insulin Resistance in Rheumatoid Arthritis
Official title: Inflammation and Insulin Resistance in Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Rheumatoid Arthritis
Keywords: RA
Rheumatoid Arthritis
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
Collaborators: name: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First posted: 2008-09-30
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Rheumatoid arthritis (RA) is a form of arthritis that causes pain, swelling, stiffness, and loss of function in the joints. Over time, joint deformity, joint destruction, and loss of function can occur. Current treatment aims to improve symptoms, but there is no cure for the disease. Pioglitazone is drug that is effective in treating people with diabetes. This study will determine whether pioglitazone can also be used to effectively treat people with RA.

Detailed description: RA is an autoimmune disease that causes long-term inflammation of the joints and sometimes other body tissues, too. Recent studies have found that there is an increased prevalence of coronary artery atherosclerosis, metabolic syndrome, and insulin resistance among people with RA. Furthermore, insulin resistance, which can lead to hyperinsulinemia-too much insulin in the blood-has been associated with RA disease activity and the severity of coronary artery atherosclerosis. These correlations suggest that inflammation and hyperinsulinemia somehow interact and facilitate one another.

Pioglitazone is a prescription drug that reduces insulin resistance and is currently used to treat people with diabetes. This study will determine whether pioglitazone can also be used to effectively treat people with RA. Specifically, the study will evaluate the effect of pioglitazone on inflammation, insulin resistance, and atherosclerosis.

Participation in this study will last about 20 weeks. At an initial 1-hour screening, participants will undergo a physical examination, medical history review, blood sampling, and, if female, a urine pregnancy test. Eligible participants will then return for the first of six monthly study visits. At this first visit, participants will be randomly assigned to receive either pioglitazone or placebo, both of which will be taken daily for 8 weeks. This will be followed by a 4-week wash-out period, during which no study treatments will be taken. Then, at Week 12, participants will begin daily treatments of whatever they were not assigned to originally. This second treatment phase will also last for 8 weeks.

All of the study visits will involve the same tests and procedures. The morning before each study visit, participants will collect their urine in a jug, which they will bring to the clinic. Participants will then undergo blood sampling, blood pressure measurements, and artery stiffness measurements. During the study visits at Weeks 4, 8, 16, and 20, participants will be asked to report on their symptoms, pain, and any adverse effects.

Eligibility criteria: Inclusion Criteria:

* Meets the American College of Rheumatology (ACR) criteria for the diagnosis of rheumatoid arthritis (RA)
* Stable disease activity, as evidenced by no change in immunomodulating or anti-inflammatory therapy in the 1 month before study entry
* Moderate disease activity, as reflected by a minimum of three swollen and tender joints
* If female of childbearing potential, willing to use effective method of contraception

Exclusion Criteria:

* Allergic to pioglitazone
* Active cancer (other than skin cancer)
* HIV infected
* Currently receiving dialysis
* Received an organ or bone marrow transplant
* Heart failure
* Severe edema, as judged by the principal investigator
* Diabetes mellitus requiring drug therapy: levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than twice the upper limit of normal
* Underwent major surgery in the 3 months before study entry
* Severe comorbid condition that is likely to compromise survival or study participation
* Currently receiving gemfibrozil or rifampin
* Osteoporosis and not receiving osteoporosis medications
* Unwillingness, or other inability, to cooperate with study procedures
* Pregnancy

Primary outcomes:
measure: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28)
timeFrame: Measured after 8 weeks of treatment
measure: Homeostasis Model Assessment (HOMA) for Insulin Sensitivity
timeFrame: Measured after 8 weeks of treatment
Secondary outcomes:
measure: C-reactive Protein (CRP)
timeFrame: Measured after 8 weeks of treatment
measure: ESR
timeFrame: baseline and after 8 weeks on either placebo or pioglitazone
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt Clinical Research Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: Charles M. Stein, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ormseth MJ, Oeser AM, Cunningham A, Bian A, Shintani A, Solus J, Tanner S, Stein CM. Peroxisome proliferator-activated receptor gamma agonist effect on rheumatoid arthritis: a randomized controlled trial. Arthritis Res Ther. 2013;15(5):R110. doi: 10.1186/ar4290.
citation: Ormseth MJ, Oeser AM, Cunningham A, Bian A, Shintani A, Solus J, Tanner SB, Stein CM. Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor gamma agonist therapy. Arthritis Rheumatol. 2014 Sep;66(9):2331-8. doi: 10.1002/art.38686.